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INTRODUCTION 
Ovaries are paired organs measuring 4 x 2.5 x 1.5 cm each in dimension
1
 
situated one on either side of the uterus close to lateral pelvic wall. 
Pathology of ovary is most difficult gynaecological disease to evaluate 
clinically
2
. 
Ovarian cancers account for 25% of all gynaecological malignancies and 
fourth most common cause of death from cancers of female genital tract in western 
world
3
. 
Ovaries are subjected to monthly endocrine and traumatic insult and hence it 
becomes a   prime site of carcinogenesis. 
The primary and secondary carcinomas of ovary are frequent with variety of 
histological pattern, which is seen in all age and ethnic groups
2
. 
50% of ovarian tumours are benign tumours, of malignant tumours 90% are 
epithelial tumours.
4
 
  
1
AIMS AND OBJECTIVES 
* To study the incidence of ovarian germ cell tumours in patients admitted in 
Institute of Obstetrics and Gynaecology (MMC), Egmore, Chennai during 
the period of 2007, January to 2012, October. 
* To study the histo-morphological features of germ cell tumours including  
tumour size, macroscopic appearance, histological type, stage.  
 
* To study the immunohistochemical expression of CD117 in germ cell 
tumours of ovary. 
 
* To determine the correlation of CD117 expression with known prognostic 
factors such as tumor size, histological type, stage  and also with the  
outcome of the disease.  
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REVIEW OF LITERATURE 
ANATOMY: 
EMBYOLOGY: 
Ovaries are almond shaped structures measuring 4 x 2.5 x 1.5cm
1
 located in 
the ovarian fossa in the pelvic wall. They are attached to the broad ligament and 
held in situ by the by suspensory ligament containing ovarian vessels and nerves. 
They are grayish pink in colour with smooth exterior surface before ovulation. The 
surface becomes distorted by scarring due to degeneration of successive corpora 
lutea. 
The gonads appear as genital or gonadal ridges, formed by proliferation of 
coelomic epithelium. The primitive germ cells in the wall of the yolk sac migrate 
along the mesentery of the lined gut to reach the primitive gonads by 5
th
 week and 
invade the genital ridges by 6
th
 week
5
. 
Shortly before the arrival of germ cells, the coelomic epithelium proliferate 
and penetrate the underlying mesenchyme in the form of primitive sex cords which 
are connected to the surface epithelium. This stage is known as indifferent gonad. 
The primitive sex cords dissociate in to irregular cell clusters, which are replaced 
by vascular stroma forming the ovarian medulla. 
3
The cortex constituting one half to 2/3
rd
 of depth of ovary, thus appearing 
primarily a cortical structure unlike testis. The epithelial cells proliferate forming 
cortical cords which penetrate the underlying mesenchyme. These cell cords split 
in to isolated cell clusters with each clusters surround one/more primitive germ 
cell. The germ cells develop in to oogonia while surrounding cells become the 
follicular cells
6
. 
HISTOLOGY: 
The surface of the ovary is covered by single layer of cuboidal cells, which 
forms the germinal epithelium. This is continuous with the mesothelial covering, 
the mesovarium. Beneath the epithelium, there is tough tissue coat called tunica 
albuginea under which lies the thick cortex and thin medulla. 
The cortex makes the major part of the ovary surrounding the medulla. The 
follicles are surrounded by dense stroma composed of thin collagen fibres and 
numerous fusiform like fibroblasts forming characteristic whorls. The boundary 
between the cortex and medulla is indistinct. The medulla is richly vascular 
composed of spiral arteries and numerous veins in a loose connective tissue stroma 
made of smooth muscles and elastic fibres. 
 The ovarian follicles of varying sizes surround the developing ova.  
4
Primordial follicle:  
 At birth, the cortex contains a superficial zone of primordial follicles, 
consisting of primary oocytes, each surrounded by a single layer of flat follicular 
cells. During childhood and even in child bearing period, many degenerate forming 
atretic follicle. 
Primary follicle: 
 The follicular cells undergo rapid mitotic proliferation to form a 
multilayered membrane granulosa, surrounding the oocyte. The stromal cells 
immediately surrounding the follicle differentiate into theca internal being spindle 
shaped and later accompanied by fibrous theca externa. As the oocyte grows, it 
secretes a homogenous proteoglycan rich acidophilic refractile layer, the zona 
pellucida. 
Secondary follicles: 
 A hyaluronic acid rich fluid called the liquor folliculi begins to form 
between the follicular cells. A large fluid filled space is formed –antrum folliculi, 
surrounded by a thin layer of granulosa cells, thickened at one pole of follicle to 
encompass the oocyte in a mound of cells, the cumulus oophorus. The theca 
interna becomes more prominent and cells start producing estrogenic hormone. 
5
Tertiary follicles: 
 Only one follicle from the two ovaries proceeds to the tertiary stage and 
remaining become atretic. This follicle increases in size to 2mm by taking up fluid 
to form Graffian follicle. The oocyte and its surrounding ring of cells break away 
from the wall and float freely in follicular fluid. The primary oocyte which has 
remained in first meiotic prophase since fetal life, complete its meiotic division to 
form the secondary oocyte and first polar body. The secondary oocyte begins 
second meiotic division, which is again arrested in metaphase until fertilization 
occurs. The follicle moves to the surface of cortex causing the ovarian surface to 
bulge. The tunica albuginea and epithelium are eroded and the follicle develops an 
aperture to release its contents into peritoneal cavity. 
Atretic follicles: 
 These are formed by degeneration of follicles at all stages of oocyte 
development from the embryonic period onwards. The follicular remnants are 
invaded by blood vessels, macrophages and connective tissue, which ultimately 
converts it in to a small white fibrous body. 
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Corpus luteum: 
 After ovulation, the walls of the empty follicle collapse and fold. The 
remaining granulosa cells increase in size and synthesize a cytoplasmic pigment 
(lutein). These granulosa lutein cells form most of corpus luteum, smaller, more 
numerous cells, derived from theca lutein cells, infiltrate the cellular mass. Lutein 
cells are grouped into small clusters, each of which is surrounded by a little 
connective tissue. These secrete estradiol, progesterone and testosterone. If the 
oocyte is not fertilized, the corpus luteum functions for 12 to 14 days then 
atrophies into corpus luteum of menstruation. The lutein cells undergo fatty 
degeneration and fibrosis to form a scar like corpus albicans. If fertilization does 
occur, the corpus luteum of menstruation grows to form the corpus luteum of 
pregnancy, which is then metabolically active till 2 months of gestation
7
. 
Corpus albicans: 
 Regressing corpus luteum invaded by connective tissue forms corpus 
albicans. 
 In early stage it may contain hemosiderin laden macrophages. Mature 
corpus albicans is well circumscribed structure with convoluted borders almost 
entirely of densely packed collagen fibers with a few admixed fibroblasts. 
7
 Most of them are eventually resorbed and replaced by ovarian stroma, 
although corpora albicantia often persists in medulla of post menopausal women.  
 
Hilus cells: 
 Found in ovarian hilus. Cells measuring 15-25µm in diameter, oval to round 
cells with abundant eosinophilic cytoplasm with vesicular nuclei and 2 or more 
prominent nucleoli. The cytoplasm may contain reinke‘s crystal, lipids, lipochrome 
pigment. 
 These cells are morphologically similar to testicular Leydig cells. 
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Rete ovary: 
 Ovarian homologue of rete testes, consisting of a network of tubules with 
intra luminal polypoidal proliferation lined by columnar to flat epithelium. These 
tubules are surrounded by spindle cell stroma. 
Risk factors: 
The aetiology of ovarian cancers are multifactorial, with genetic, 
environmental, and reproductive factors directly or indirectly involved in 
carcinogenesis. 
Genetic factors: 
A family history of ovarian cancer is the most significant risk factor. 
Approximately 10% of all ovarian cancers can be associated with a familial genetic 
predisposition. The risk depends on the number of their first and second degree 
relatives with ovarian cancer and their age at diagnosis. 
Some of the genes implicated in causation of ovarian cancers are P53, 
BRCA-1, and BRCA-2. 
9
Hereditary syndromes associated with ovarian cancers are Lynch-II 
syndrome, hereditary site specific ovarian cancer syndrome and sweyer syndrome 
is associated with dysgerminoma. 
Environmental factors: 
Consumption of coffee and tobacco has an association with etiology of 
ovarian cancers. Obesity is an also important factor. 
Reproductive factors: 
Multiparous women are at increased risk than parous women. First 
pregnancy at an early age offers protection against ovarian cancers. Breast feeding 
offers protection against ovarian cancer. 
Infertility is an independent risk factor for ovarian cancer. 
Oral contraceptive pills use offers protection. 
Clinical presentation: 
 Ovarian tumours are known to present with variable clinical features, these 
range from patient being absolutely asymptomatic, accidental detection during 
10
laporotomy for other reasons, caesarian section to patient presenting as acute 
abdomen due to torsion or rupture. 
The commonest symptoms are those due to asymptomatic slow growing abdominal 
or pelvic mass, with or without pain and tenderness. Nowadays, most cases are 
detected on USG done for other reasons. 
Epidemiology: 
 Early knowledge of the ovary and the gradual evolution of use of the word 
‗ovary‘ refering to the female gonad have been reviewed by Gruhn8. 
Worldwide, ovarian cancer is the sixth most common cancer in women and 
the  seventh most common cause of cancer death. There are about 2 lakh and four 
thousand  new cases and 1 lakh and 25 thousand deaths were reported annually
 3
. 
  Ovarian carcinoma is the fifth most common malignancy in most western 
countries and   fourth common cause of cancer mortality.  
In the Western hemisphere, it accounts for 4% of cancer in women and is the 
most frequent cause of death due to gynecological cancers.  
In general, the disease is more common in industrialized nations where 
parity is lower, but there are notable exceptions such as Japan which has a low 
11
parity and  low rate of ovarian cancer. The incidence varies widely among different 
ethnic groups. The lifetime risk varies widely from 0.45% in Japan to 1.7% in 
Sweden.  
Germ cell tumours constitute the second largest group of ovarian neoplasms, 
comprises 20% of all ovarian neoplasms.  
It‘s only after studies by Teilum 9,10  on the homology of ovarian and 
testicular neoplasms and studies by Friedman, Moore 
11
and Dixon
12
, Moore
13
 on 
testicular tumors, and those by Friedman
 14
 on related extragonadal neoplasms 
group of neoplasm belonging to germ cell origin was proposed. These views were 
also supported by the embryologic studies of Witschi 
5
and Gillman 
15
, and later by 
experimental studies of Stevens 
16-18
 and Pierce et al
19,20.
 on germ cell tumors in 
rodents. 
  
12
 TEILUM’S HYPOTHESIS 
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Robert Meyer coined the term ‗disgerminoma‘ (soon changed  it as 
dysgerminoma) Schiller made  important contributions, writing his earliest papers 
on dysgerminoma in 1934 
21
. He also pointed  about  the granulomatous infiltrate 
of dysgerminoma, which had previously  been mistaken as representing 
tuberculosis, was unrelated to that infectious disease. 
Ovarian surface epithelial neoplasms are common followed by germ cell 
neoplasms. 
WHO classification of ovarian tumours is given in Annexure II. 
Germ cell tumours are encountered at all ages from infancy to old age, but 
are seen most frequently from first to 6
th
 decades of life. 
In children and adolescents, more than 60% of ovarian neoplasms are of 
germ cell origin and one third are malignant. 
DYSGERMINOMA: 
The term dysgerminoma was first introduced by Meyer in 1931. 
In view of strong resemblance to their testicular counterpart seminoma, 
Masson called it as ovarian seminoma
22
. 
14
HISTOGENESIS: 
Dysgerminoma is a tumour composed almost entirely of cell population that 
resembles primordial germ cells
23
. These cells are believed to be arrested at  
developmental stage at which they have not yet gained the ability for further 
differentiation. The amount of DNA in the nuclei of dysgerminoma cells is twice 
that of  lymphocyte nuclei  in all the cases studied. 
In most cases studied, dysgerminoma is not associated with endocrine 
symptoms. 
PREVALENCE: 
Dysgerminoma accounts for 1-2% of primary ovarian malignant 
tumours
24,25
. Until 1950, only 427 cases recorded in literature. 
Dysgerminoma is the most common germ cell malignancy occurring in pure 
form. 
CLINICAL FEATURES: 
Dysgerminoma is reported from ages of 7months to 70yrs
24
. Common in 
second and third decades of life.50% of patients are under 20 years of age, 80% of 
15
patients are under 30 yrs of age
24,26,27,28
. Duration of symptoms is short, presenting 
symptoms are lower abdominal mass and abdominal pain. 
Dysgerminoma is one of the common ovarian neoplasm observed during 
pregnancy, the others are benign serous cystadenoma and benign cystic teratoma.  
GROSS: 
Dysgerminoma is usually unilateral. It is more common in right side of the 
ovary (approximately 50% of cases)
24
.  
They are usually solid in nature with a lobulated contour with a smooth grey 
white slightly glistening fibrous capsule, red brown or yellow discoloration caused 
by haemorrage or necrosis is also seen. Cystic areas are very rare in pure 
dysgerminomas.  
MICROSCOPY: 
Histologically identical to classical seminoma of testis. It consists of islands, 
strands or aggregates of large uniform cells, surrounded by connective tissue 
stroma rich in lymphocytes.Cells are round to oval with vesicular nucleus, sharp 
nuclear membrane, two prominent eosinophilic nucleoli, abundant granular 
eosinophilic or clear cytoplasm. Mitotic activity is almost always present. 
16
Cytoplasm contains glycogen demonstrated by PAS. They may show positive 
alkaline phosphatase reaction beneath the cytoplasmic rim. 
The stroma that surrounds the tumour cells is almost always infiltrated by 
lymphocytes. Occasionally lymphoid follicles with germinal centres may be seen. 
Rarely a granulomatous reaction can also be observed. 
CLINICAL BEHAVIOUR: 
Dysgerminoma is a malignant neoplasm capable of both metastatic and local 
spread. Tumours are highly sensitive to radiotherapy. Dysgerminoma similar to 
seminoma, associated with elevated levels of LDH. 
Placental alkaline phosphatase produces membranous staining of 
dysgerminoma, can be used to diagnose dysgerminoma immunohistochemically. 
Patients with pure dysgerminoma carry very favourable prognosis. 
5yr survival rate of patients with unilateral encapsulated dysgerminoma is 
90%. 
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TREATMENT: 
Dysgerminoma like its counterpart in testis, seminoma is highly sensitive to 
radiotherapy. It responds well to combination chemotherapy of bleomycin, 
etoposide and cisplatin. 
Patients with bilateral or disseminated dysgerminoma and patients with 
unilateral encapsulated tumours no longer desirous of having children were treated 
by hysterectomy and bilateral salphingo oopherectomy followed by radiation to 
abdominal and to mediastinal lymph nodes. 
Nowadays, such patients are treated with three to four cycles of combination 
chemotherapy with good results. 
YOLK SAC TUMOUR: 
Yolk sac tumour is a malignant germ cell neoplasm, thought to arise from 
undifferentiated and multipotential embryonal carcinoma by selective 
differentiation towards yolk sac or vitelline  structures
29,30,31
. 
AFP is elevated grossly in yolk sac tumours.AFP has been identified in cells 
of yolk sac tumour, embryonal carcinoma and eosinophilic PAS positive, diastase 
resistance globules. 
18
PREVALENCE: 
Second most common malignant ovarian germ cell neoplasm
32
 after 
dysgerminoma. Most frequent in second and third decades. 
CLINICAL FEATURES: 
Most patients present with abdominal enlargement pain, lower, abdominal or 
pelvic mass. They are not associated with endocrine symptoms. 
GROSS: 
They tend to be large with an average size of 16cm.Cut surface is tan white 
or gray with small cysts and areas of haemorrhage and necrosis. 
HISTOPATHOLOGY: 
Two most  common pattern. 
 Reticular or microcystic pattern 
 Endodermal sinus pattern34.  
Endodermal sinuses or perivascular formations (also known as Schiller–
Duval bodies) are hallmark of this tumor. These structures are also known as 
sinuses of Duval, Schiller–Duval bodies, or glomerulus-like structures and 
19
resemble superficially the structure of immature renal glomeruli. When sectioned 
longitudinally, the perivascular structures consist of a central connective tissue 
core containing a longitudinal vessel surrounded by epithelial-like cells that often 
form small papillary formations  that  projects  into the surrounding capsular 
sinusoid space.  
Reticular pattern consists of loose meshwork of microcystic spaces lined by 
single layer of flattened or cuboidal cells. Cells have clear or amphophilic 
cytoplasm and atypical hyperchromatic nucleus. 
Other patterns: 
Alveolar glandular pattern. 
Solid pattern 
Hepatoid pattern 
Glandular pattern-with zone of endometrioid glands or glands of intestinal 
type. 
Eosinophilic PAS positive, diastase resistant hyaline globules are 
characteristic finding in yolk sac tumours, most often found in reticular and 
20
endodermal sinus patterns. They are composed of laminin and collagen IV that 
resembles basement membrane ultrastucturally
35,36
. 
IHC: 
Most important immunohistochemical finding in yolk sac tumour is positive 
staining for AFP, α1 antitrypsin37 and PLAP. Extra cellular hyaline material is 
laminin positive
36
. 
Yolk sac tumour is cytokeratin positive but epithelial membrane antigen 
negative. 
EMBRYONAL CARCINOMA: 
It occurs almost exclusively in children and young women
35,36
. The typical 
presentation is with pelvic or abdominal pain or palpable abdominal mass. Most 
patients have positive pregnancy test, or an elevated serum β HCG concentration, 
50% of patients have precocious pseudopuberty
38
.Embryonal carcinoma is 
virtually never bilateral, unilateral salphingo oopherectomy is the appropriate 
treatment. 
Before effective combination chemotherapy was available, embryonal 
carcinoma was often rapidly fatal. At present patients with completely resected 
21
embryonal carcinoma are treated with post-operative cisplatin based adjuvant 
chemotherapy with nearly complete success. 
22
GROSS: 
Embryonal carcinoma is a large solid neoplasm with an average diameter of 
15-17cm.The cut surface is fleshy and tan or gray with small cysts and areas of 
haemorrhage and necrosis. 
HISTOPATHOLOGY: 
Tumour cells have large vesicular nuclei with coarse chromatin and one or 
two prominent nucleoli. The cytoplasm is abundant and amphophilic or clear. The 
tumour cells grow in nests, sheets, punctuated by occasional clefts, glands or 
papillae. Stroma is loose and edematous. 
IHC: 
Immunostains for CK and CD30 are positive with a membranous pattern of 
staining. 
It shows nuclear staining for OCT4 but staining for CD117 and EMA are 
negative. 
23
POLYEMBRYOMA: 
Rare form of malignant germ cell tumour with features intermediate between 
embryonal carcinoma and more differentiated forms of malignant germ cell 
tumours
39,40
. 
Microscopically is composed of numerous embryoid bodies growing in a 
primitive embryonal stroma. Embryoid bodies resembles 14-20wks embryo. They 
contain an embryonal disc composed of tall columnar cells with hyperchromatic 
nuclei, on one side of disc is an amniotic cavity and on other side yolk sac lined by 
α fetoprotein positive cells. 
CHORIOCARCINOMA: 
Pure primary ovarian choriocarcinoma of germ cell origin is extremely rare. 
CLINICAL FEATURES: 
Choriocarcinoma of ovary occurs in children and young women
41
.The 
clinical presentation is abdominal pain and abnormal vaginal bleeding. 
Pregnancy test is positive and serum β HCG is elevated42. 
24
Choriocarcinoma of ovary is unilateral and is treated by salphingo 
oopherectomy. Surgery is followed by combination chemotherapy with platinum 
based regimen. Chemotherapy and prognosis differ in gestational choriocarcinoma 
.There are no morphological differences between gestational choriocarcinoma and 
choriocarcinoma of germ cell origin. 
GROSS: 
Choriocarcinoma is unilateral soft, purple red tumour with a haemorrhagic 
and necrotic cut surface. 
HISTOLOGY: 
Much of the tumour is haemorrhagic and necrotic. Cytotrophoblastic and 
syncytiotrophoblastic giant cells grow in a plexiform pattern. Cytotrophoblastic 
cells have abundant clear cytoplasm and well defined cell borders. Nuclei are 
irregular and vesicular and some contain macronucleoli. Syncytiotrophoblastic 
giant cells have abundant vacuolated basophilic or amphophilic cytoplasm in 
which there are multiple hyperchromatic nuclei. 
25
IHC: 
All trophoblastic cells are cytokeratin positive with dense staining of 
cytoplasm of syncytiotrophoblastic giant cells. Immunostains for β HCG mark the 
cytoplasm of syncytiotrophoblastic giant cells
42
. 
TERATOMA: 
BENIGN CYSTIC TERATOMA: 
Benign Cystic Teratoma is the most common ovarian neoplasm, comprising 
25% or more of all ovarian tumours. 
They are cystic or merely solid tumours that contain various mature tissues 
derived from one or more of the embryonic germ layers, ectoderm, mesoderm and 
endoderm. 
CLINICAL FEATURES: 
Peak incidence is between 20 and 29yrs.Symptoms such as pelvic pressure 
or pain appear when tumour attains larger size. The most common serious 
complications are torsion, found in 3-10% of cases. Cystectomy performed 
laporoscopically or at laporotomy is adequate treatment. 
26
GROSS: 
They are nearly always cystic tumours average diameter 7-8cm on cross 
section, there is unilocular or multilocular cyst with solid protuberance called 
dermoid papilla in the wall. The cyst contains hair, grumous material or oily or 
serous liquid. Cartilage, bone  or teeth may be found. 
HISTOLOGY: 
Benign teratomas contain a varied mixture of ectodermal, mesodermal and 
endodermal structures distributed in an organised fashion. Ectodermal derivatives 
such as skin, hair follicle and sebaceous and sweat glands are most common, when 
they dominate, tumour is refered to as dermoid cyst. 
IMMATURE TERATOMA: 
Immature Teratoma is one of the most common malignant germ cell tumours 
of ovary. 
CLINICAL FEATURES: 
It occurs predominantly in children and young women. Patients present with 
pelvic or abdominal pain, mass. Serum α-fetoprotein level can be elevated in 
patients with pure immature teratoma, often modest elevation of tumour markers 
27
CA125
43-46
. Bilaterality is exceptional. Spreads mainly by implantation on pelvic 
and abdominal peritoneum in the omentum. 
Patients with localized stage1A tumours are treated by unilateral salphingo-
oopherectomy, a few patients have been treated by cystectomy followed by 
chemotherapy. Cisplatin containing regimens such as BEP are highly effective 
forms of adjuvant chemotherapy for patients with no residual tumour after, surgery 
with survival rates of  90-100 percent. 
GROSS: 
Immature teratoma is predominantly solid unilateral tumour that averages 
18cm in diameter. Solid component are gray or brown and can be soft or hard and 
gritty, scattered small cysts are typically seen on the cut surface. 
HISTOPATHOLOGY: 
Tissues derived from all three germ cell layers are present and a mixture of 
mature and immature elements is found in most tumours. Ectodermal and 
mesodermal derivatives typically predominate among immature elements. 
STRUMA OVARII: 
28
Struma ovarii is a teratoma in which thyroid tissue predominates. More than 
50% of thyroid tissue
47
 should be present to call it as struma ovarii. 
CLINICAL FEATURES: 
Occurs mainly in women older than 40 yrs, only 10% of patients present 
with hyperthyroidism. 
GROSS: 
Struma ovarii is red, green or tan with a glairy meaty appearance. 
MICROSCOPY: 
It is composed of follicles lined filled with eosinophilic colloid and lined by 
cuboidal or columnar cells with uniform round nuclei. 
IHC: 
Immunostains for thyroglobulin positive in colloid and follicular cells are 
positive for TTF-1. 
29
TREATMENT: 
Cystectomy is adequate treatment. 
MALIGNANT MIXED GERM CELL TUMOUR: 
They contain a mixture of various types of pure germ cell tumours. They 
constitute 5-20% of all malignant germ cell tumours. 
CLINICAL FEATURES: 
They occur in children and young women. Average age group is 16 yrs. 
They present with abdominal pain or palpable abdominal mass. 
About one third of patients present with precocious puberty. 
50% of patients present with positive pregnancy test. 
GROSS: 
They tend to be large averages about 15cm in diameter. Dysgerminoma is 
fleshy and gray, tan or white, yolk sac tumour varies in colour contains small cysts 
and often have areas of necrosis. 
30
MICROSCOPY: 
There are two elements in 80% of germ cell tumours. Dysgerminoma is the 
most frequent element followed by yolk sac tumour and immature 
teratoma.Embryonal carcinoma, choriocarcinoma and polyembryoma are less 
common.      
TREATMENT: 
Encapsulated unilateral tumours (stageIA) are best treated by salphingo 
oopherectomy. More advanced cases are treated by abdominal hysterectomy, B/L 
salphingo oopherectomy. Chemotherapy is administered to most patients except 
stage I. 
C-KIT: 
The proto-oncogene c-kit encodes for a 145–160 kDa, type III 
transmembrane tyrosine kinase receptor known as c-kit or CD117
48,49, 
which 
belongs to the same family of receptors as platelet-derived growth factor(PDGFR) 
and colony-stimulating factor-1(CSF-1).
50.
 
The binding of stem cell factor, the ligand for this receptor, leads to the 
dimerization of c-kit proteins, thus initiating a signaling cascade that ultimately 
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induces cell growth. Expression of c-kit is essential in the development of some 
cell types, including germ cells, melanocytes, mast cells, erythrocytes, and 
interstitial cells of Cajal
48,51-53
. 
In addition, expression of this receptor may be seen in other histologically 
normal cell types, such as breast epithelial cells, astrocytes, renal tubule cells, 
purkinje cells, parotid acini, and endometrial cells
53-55.
  
Aberrant expression of this C-kit has also been implicated in the 
development of a number of human cancers, including malignancies of the lung, 
breast, skin, uterus, endometrium, urinary bladder, and ovary, as well as in certain 
types of leukemia, gastrointestinal stromal tumors (GISTs), ewing‘s sarcoma and 
germ cell tumors
55–75
.
 
The advent of therapies targeted to c-kit have proven highly 
effective in treating some of  the  cancers  that over express this receptor, such as 
CML and GISTs.
76-79
  
M Sever et al
80
 studied the c-kit expression in 30 cases of dysgerminoma. 
Immunohistohemical staining done with a polyclonal anti-CD117 antibody. 
Staining was graded in a semiquantitative manner as follows:  
no staining    - NEGATIVE 
1-10% staining  - 1+ 
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10-29% staining - 2+ 
30-50% staining - 3+ 
 > 50% staining - 4+ 
In his studies 26 (87%) showed immunoreactivity for CD117. In total, 33% 
of cases (26) demonstrated 4+ staining, 30% of cases(9)  demonstrated 3+ 
staining,10% of cases (3)  demonstrated 2+ staining; 13% of cases(4) demonstrated 
1+ staining; and 13% of cases (4) demonstrated no staining. In conclusion, CD117 
positivity was detected in 87% of ovarian dysgerminomas, a finding that is 
correlating with previously reported frequencies of CD117 expression in 
seminomas about 78–100%. Thus, antibodies to c-kit may be a useful diagnostic 
marker for ovarian dysgerminoma. Though prognosis of patients with 
dysgerminoma is generally good, this receptor could potentially serve as a target 
for site-specific immunotherapy as an alternative and or complement to 
conventional treatment options.  
IMMUNOHISTOCHEMISTRY: 
Albert Coons et al in 1941 first labeled antibodies directly with fluorescent 
isocyanate. Nakane and Pierce et al in 1966, introduced indirect labeling technique 
in which unlabeled antibody is followed by second antibody or substrate. Various 
stages of development of Immunohistochemistry include peroxidase – 
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antiperoxidase method (1970), alkaline phosphatase labeling (1971), avidin biotin 
method (1977) and two layer dextrin polymer technique (1993)
81
. 
ANTIGEN RETRIEVAL: 
Antigen retrieval can be done by the following different techniques to 
unmask the antigenic determinants of fixed tissue sections. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976 introduced this technique to breakdown formalin cross 
linkages and to unmask the antigen determinants. The most commonly used 
enzymes include trypsin and proteinase
82
. The disadvantages include over 
digestion, under digestion and antigen destruction. 
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MICROWAVE ANTIGEN RETRIEVAL: 
This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections in 
various buffers for rapid and uniform heating. Antibodies against CD117  work 
well after heat pretreatment in this method
81
. 
PRESSURE COOKER ANTIGEN RETRIEVAL: 
Miller et al in 1995 compared and proved that pressure cooking method has 
fewer inconsistencies, less time consuming and can be used to retrieve large 
number of slides than in microwave method
83
. 
PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pretreatment destroys antigenicity. 
Nuclear details are damaged in poorly fixed tissues. Fibers and fatty tissues tend to 
detach from slides while heating. Not all antigens are retrieved by heat 
pretreatment and also some antigens like PGP 9.5 show altered staining pattern. 
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DETECTION SYSTEMS: 
After addition of specific antibodies to the antigens, next step is to visualize 
the antigen antibody reaction complex. The methods employed are direct and 
indirect methods. 
In the direct method, primary antibody is directly conjugated with the label. 
Most commonly used labels are flouro-chrome, horse radish peroxidase and 
alkaline phosphatase. Indirect method is a two-step method in which labeled 
secondary antibody reacts with primary antibody bound to specific antigen. The 
use of peroxidase enzyme complex or avidin biotin complex further increases the 
sensitivity of immunohistochemical stains
81
. 
In 1993, Pluzek et al introduced enhanced polymer one step staining, in 
which large numbers of primary antibody and peroxidase enzymes are attached to 
dextran polymer back bone. This is the rapid and sensitive method
84
. 
Dextran polymer conjugate two step visualization system is based on 
dextran technology in Epos system. This method has greater sensitivity and is less 
time consuming. 
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MATERIALS AND METHODS 
This study is a retrospective descriptive study of germ cell tumours of ovary 
conducted in the Institute of obstetrics and gynaecology, Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai during the period 
between January 2007 and October 2012.  A total of 725 ovarian neoplasms were 
received over the study period, out of which 487 cases were benign, 34 cases were 
border line and  204 cases were malignant. 
SOURCE OF DATA: 
All cases of ovarian neoplasm received in Institute of Obstetrics and 
Gynaecology, Madras Medical College and Rajiv Gandhi Government General 
Hospital were studied. 
INCLUSION CRITERIA: 
All malignant germ cell tumours of ovary. 
EXCLUSION CRITERIA: 
 Benign germ cell tumours of ovary. 
 Surface epithelial , sex cord stromal and metastatic tumours. 
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METHOD OF DATA COLLECTION: 
The detailed history of cases including age, presenting complaints, duration 
of complaints, USG and CT findings, any hormonal elevation (AFP, β-HCG, 
LDH), were taken. 
In macroscopy, the appearance of external surface and cut surface of the 
tumours are studied. 
In microscopy, type of tumour, if mixed germ cell tumour, components of 
MGCT, omental infiltration by tumour, malignant cells in ascitic fluid, and 
peritoneal washings, all were studied. 
The follow up data of these patients including the details of months of 
follow up, number of chemotherapy cycles given and outcome of the patient are 
studied. 
The proforma for obtaining clinical details from the patient is given in 
Annexure I. 
 Representative formalin fixed paraffin embedded tissue samples of all the 
30 cases  of were subjected to immunohistochemistry (CD117). 
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IMMUNOHISTOCHEMICAL EVALUATION: 
Immuohistochemical analysis of a panel of marker CD117 were done in 
paraffin embedded tissue samples using Super-sensitive30 polymer HRP system 
based on non-biotin polymeric technology. 4 μ thick sections from formalin fixed 
paraffin embedded tissue samples were transferred on to gelatin coated slides. Heat 
induced antigen retrieval was done. The antigen was bound with mouse 
monoclonal antibody (Biogenex) against CD117 protein and then detected by the 
addition of secondary antibody conjugated with horse radish peroxidase-polymer 
and diaminobenzidine substrate. The step by step procedure of 
Immunohistochemistry is given in Annexure IV. 
INTERPRETATION AND SCORING SYSTEM: 
Immunohistohemical staining with a anti-CD117 antibody was done 
tumours show a peri membranous positivity of CD117. 
Staining was graded in a semiquantitative manner as follows:  
no staining       - NEGATIVE 
1-10% staining  - 1+ 
10-29% staining  - 2+ 
30-50% staining - 3+ 
 > 50% staining  - 4+ 
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STASTISTICAL PACKAGE: 
The statistical analysis was performed using statistical package for social 
science software version 11.5 which consisted computing the frequency counts and 
percentages for qualitative variables and mean for the quantitative variables. The 
expression of CD 117 is correlated with different histological subtypes of germ cell 
tumours, stage of the disease, USG findings and also with outcome of the disease 
using pearson chi square test. 
The various clinical parameters like gross, USG findings, HPE subtypes, 
type of surgical procedure ,chemotherapy given  are also correlated with outcome 
of the disease. 
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OBERVATION AND RESULTS 
* In our institute,  a total of 725 ovarian neoplasms were received. Out of 
which 487 cases were benign, 34 cases were borderline and 204 cases were 
malignant (TABLE 1 and CHART 1). 
TABLE – 1 
DISTRIBUTION OF BENIGN, BORDERLINE AND  MALIGNANT CASES 
Tumour type No of cases Percentage 
Benign 487 67.13% 
Borderline 34 4.7% 
Malignant 204 28% 
 
* Out of 725 cases surface epithelial tumours (75.5%) were common followed 
by germ cell tumours (16.5%) followed next by sex cord stromal tumours 
(7.2%) and finally metastatic tumours which account for 0.8% (TABLE 2 
and CHART 2). 
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TABLE – 2 
DISTRIBUTION OF OVARIAN TUMOURS ACCORDING TO 
HISTOLOGICAL TYPE 
 
TUMOUR TYPE NO OF CASES PERCENTAGE 
Surface epithelial 
tumours 
547 75.5% 
Germ cell tumours 120 16.5% 
Sex cord stromal 
tumours 
52 7.2% 
secondaries 6 0.8% 
TOTAL 725 100% 
 
* In surface epithelial tumours, commonest is benign serous cystadenoma. In 
germ cell tumours benign cystic teratoma is common. 
* In malignant tumours, papillary serous cystadenocarcinoma was very 
common (90cases). 6 cases of clear cell carcinoma has been reported. 
* In 120 germ cell tumours, 88 were benign cystic teratoma, 2 cases were 
struma ovarii and 30 were malignant germ cell tumours (TABLE 3 and 
CHART 3 ). 
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TABLE - 3 
SUBCLASSIFICATION OF GERM CELL TUMOURS BASED ON 
HISTOLOGICAL TYPE 
 
Tumour type No of cases Percentage. 
Mature cystic teratoma 88 73.33% 
Struma ovarii 2 1.67% 
Malignant germ cell tumours 30 25% 
TOTAL 120 100% 
 
* In malignant germ cell tumours, dysgerminoma is very common accounting 
for 11 cases out of 30 malignant germ cell tumours, followed by mixed germ 
cell tumours which constitute about 10. 
 
* In sex cord stromal tumours, granulosa cell tumours were common which 
constituted 27 cases out of which 5 cases were malignant. Rare cases like 
steroid cell tumour (2), sclerosing stromal tumour (1) has also been reported. 
 
* In the malignant germ cell tumours, 11 were dysgerminoma, 10 were mixed 
germ cell tumour, 4 were  yolk sac tumour  and  5 were  immature teratoma. 
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 TABLE – 4 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO TUMOUR TYPE 
TYPE NUMBER PERCENTAGE 
DYSGERMINOMA 11 36.66% 
YOLK SAC TUMOUR 4 13.34% 
IMMATURE TERATOMA 5 16.66% 
MIXED GCT 10 33.34% 
TOTAL 30 100% 
 
* Dysgerminoma is the most common germ cell tumour in the current study, 
which constitutes about 11 cases followed by mixed germ cell tumours 
which constitute about 10 cases (TABLE 4 and CHART 4). 
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 TABLE – 5 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO AGE GROUP 
AGE NUMBER PERCENTAGE 
11-15 3 10% 
16-20 12 40% 
21-25 6 20% 
26-30 6 20% 
31-35 1 3.34% 
36-40 2 6.66% 
TOTAL 30 100% 
 
* Our patients age range from 13 to 40 yrs, with mean age of occurrence is 
22.4 yrs.  
 
* The maximum number of patients present in second decade (50%) followed 
by third decade (40%) (TABLE 5 and CHART 5). 
  
45
  
 
TABLE - 6 
DISTRIBUTION OF  MALIGNANT GERM CELL TUMOURS 
ACCORDING TO LATERALITY OF TUMOURS 
SIDE NUMBER PERCENTAGE 
RIGHT 18 60% 
LEFT 11 36.66% 
BILATERAL 1 3.34% 
 
* In 30 cases  studied 18 cases are right sided, 11 cases are left sided and 1 
case  is bilateral (TABLE 6 and CHART 6). 
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TABLE - 7 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO SIZE OF THE TUMOURS 
SIZE NUMBER PERCENTAGE 
5-10 cm 5 16.66% 
11-15cm 13 43.34% 
16-20cm 4 13.34% 
21-25cm 6 20% 
26-30cm 2 6.66% 
TOTAL 30 100% 
 
* The maximum diameter of tumour is taken in to account  and the average is 
calculated. The largest diameter is about 30cm and smallest is about 8cm. 
 
* The average size of tumours is about 15.7 cm. Most of the tumours fall 
within a range of 5-15cm (about 60%) (TABLE 7 and CHART 7). 
47
  
TABLE – 8 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO GROSS FINDINGS 
 
GROSS FINDINGS NUMBER PERCENTAGE 
SOLID 8 26.7% 
CYSTIC 2 6.7% 
MIXED 20 66.6% 
TOTAL 30 100% 
 
* In macroscopy, purely solid tumours were 8, purely cystic tumours were 2 
and  mixed solid and cystic tumours were 20 (TABLE8). 
 
* From our observation dysgerminoma presents as purely solid lesions and 
mixed germ cell tumours presents as variegated appearance. One of the case 
of dysgerminoma presented with cystic change which is give in (Fig.11) 
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TABLE – 9 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO USG FINDINGS 
 
USG FINDINGS NO OF CASES PERCENTAGE 
Solid 8 26.7% 
Cystic 2 6.7% 
Mixed  echoes 20 66.6% 
 
* In ultra sound findings, out of the 30 germ cell tumours, 8 cases showed 
solid  lesions, 2 cases showed purely cystic shadows and 20 cases were 
mixed lesions (TABLE 9 and CHART 8).  
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 TABLE – 10 
DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO STAGE 
STAGE NO OF CASES PERCENTAGE 
I 11 36.7% 
II 2 6.7% 
III 17 66.6% 
IV 0 0% 
TOTAL 30 100% 
 
* FIGO staging system is followed, which is given in Annexure III. 
* In current study, stage III disease is more common constitutes about 17 cases 
followed by stage I which is about 11 cases and stage II constitutes about 2 
cases (TABLE10 and CHART 9). 
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 TABLE - 11 
PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT MALIGNANT 
GERM CELL TUMOURS 
Tumour type No of cases 
Cases showing 
c-kit positivity 
Percentage 
Dysgerminoma 11 10 90.9% 
Yolk sac tumour 4 2 50% 
Immature teratoma 5 1 20% 
Mixed germ cell 
tumour 
10 7 70% 
TOTAL 30 20  
 
* The percentage of positivity in histological subtypes  of germ cell tumours 
were compared.C –kit positivity is more in cases of pure dysgerminoma 
compared to other tumours (TABLE 11 and CHART 10) 
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 TABLE – 12 
PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT STAGES OF 
MALIGNANT GERM CELL TUMOURS 
 
STAGE NO OF CASES 
C-KIT 
POSITIVITY 
PERCENTAGE 
I 11 8 72.7% 
II 2 1 50% 
III 17 11 64.7% 
IV 0 0 0 
TOTAL 30 20 66.6% 
 
* In current study positivity rate more in stage I tumours (72.7%) followed by 
stage III (64.7%) (TABLE 12 and CHART 11). 
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TABLE – 13 
COMPARISION OF C-KIT POSITIVITY IN MIXED GERM CELL 
TUMOURS WITH AND WITHOUT DYSGERMINOMA COMPONENT 
TUMOUR TYPE 
NO OF 
CASES 
CASES 
SHOWING C-
KIT 
POSITIVITY 
PERCENTAGE 
Mixed germ cell 
tumours with 
dysgerminoma 
6 6 100% 
Mixed germ cell 
tumours without 
dysgerminoma 
4 1 25% 
TOTAL 10 7  
 
* The percentage of c-kit positivity in mixed germ tumours with and without 
dysgerminoma was compared. The positivity rate is more in the group with 
dysgerminoma component (TABLE 13 and CHART 12). 
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TABLE – 14 
CORRELATION OF EXPRESSION OF CD117 WITH USG FINDINGS 
CD117 SOLID CYSTIC MIXED TOTAL 
Pearson 
chi square 
test 
0 1(12.5%) 2(100%) 7(35%) 10(33.3%)  
 
P=0.614 
1 1(12.5%) 0(0%) 3(15%) 4(13.3%) 
2 1(12.5%) 0(0%) 3(15%) 4(13.3%) 
3 3(37.5%) 0(%) 4(20%) 7(23.3%) 
4 2(25%) 0(%) 3(15%) 5(16.7%) 
TOTAL 8(100%) 2(100%) 20(100%) 100%  
 
* CD117 expression is more common in solid tumours than cystic and lesions 
with mixed echoes, but the correlation is not statistically significant. 
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TABLE – 15 
CORRELATION OF EXPRESSION OF CD117 WITH HPE DIAGNOSIS 
CD117 
DYSGER
MI-NOMA 
YOLK 
SAC 
TUMOUR 
IMMATURE 
TERATOMA 
MIXED 
GERM 
CELL 
TUMOUR 
TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
0 1(9.0%) 2(50%) 4(80%) 3(30%) 10(33.3%) 
 
 
P=0.367 
1 1(9.0%) 1(25%) 0(%) 2(20%) 4(13.33%) 
2 3(27.3%) 0(%) 0(%) 1(10%) 4(13.33%) 
3 3(27.3%) 1(25%) 1(20%) 2(20%) 7(23.33%) 
4 3(27.3%) 0(%) 0(%) 2(20%) 5(16.67%) 
TOTAL 11(100%) 4(100%) 5(100%) 10(100%) 30(100%)  
 
* CD117 expression is more common in dysgerminoma than other germ cell 
tumour subtypes, but the correlation is not statistically significant. Out of 20 
cases showing positivity, 7 cases are showing 3+ positivity. Out of the 5 
cases showing strong c-kit positivity (4+) 3 were dysgerminoma. 
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TABLE - 16  
CORRELATION OF AGE WITH CD117 EXPRESSION 
CD 117 AGE<20 AGE>20 TOTAL 
PEARSON 
CHI SQUARE 
TEST 
0 3(30%) 7(35%) 10(33.3%) 
 
 
P=0.559 
1+ 2(20%) 4(20%) 6(20%) 
2+ 1(10%) 1(5%) 2(6.66%) 
3+ 3(30%) 4(20%) 7(23.3%) 
4+ 1(10%) 4(20%) 5(16.7%) 
TOTAL 10(100%) 20(100%) 30(100%)  
 
* Patients in age group <20 yrs exhibit more CD117 (70%) positivity than 
patients under age >20 (65%), but the correlation is not statistically  
significant. 
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TABLE – 17 
CORRELATION OF SIZE OF THE TUMOURS  WITH CD117 
EXPRESSION 
CD 117 SIZE<20cm SIZE>20cm TOTAL 
PEARSON 
CHI SQUARE 
TEST 
0 8(36.3%) 2(25%) 10(33.3%)  
 
P=0.631 
1+ 2(9.1%) 2(25%) 4(13.3%) 
2+ 3(13.6%) 1(12.5%) 4(13.3%) 
3+ 5(22.7%) 2(25%) 7(23.3%) 
4+ 4(18.2%) 1(12.5%) 5(16.7%) 
TOTAL 22(100%) 8(100%) 30(100%)  
 
* Tumours with size more than 20 cm are showing more positivity (75%) than 
tumours with size less than 20 cm (63.6%), but the correlation is not 
statistically significant. 
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TABLE - 18 
CORRELATION OF EXPRESSION OF CD117 WITH STAGE OF THE 
DISEASE 
CD117 STAGE I 
STAGE 
II 
STAGE 
III 
TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
0 3 (27.3%) 1 (50%) 6(35.3%) 10(33.3%)  
 
P=0.792 
1 1(9.1 %) 0(0.0%) 3(17.6%) 4 (13.3%) 
2 2(18.2%) 0(0.0 %) 2 (11.8%) 4(13.3 %) 
3 4(36.4%) 0(0.0 %) 3(17.6%) 7(23.3 %) 
4 1(9.1%) 1(50.0%) 3(17.6 %) 5(16.7%) 
TOTAL 11(100%) 2(100%) 17(100%) 30(100%)  
 
* Stage I tumours show more positivity than stage III tumours, but the 
correlation is not statistically significant. 
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TABLE – 19 
CORRELATION OF EXPRESSION OF CD117 WITH OUTCOME OF THE 
DISEASE 
CD 117 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
0 4(23.5%) 2(100%) 1(100%) 7(35%) 
 
 
P=0.585 
1 2(11.8%) 0(0%) 0(0%) 2(10%) 
2 2(11.8%) 0(0%) 0(0%) 2(10%) 
3 3(35.3%) 0(0%) 0(0%) 3(30%) 
4 6(17.6%) 0(0%) 0(0%) 6(15%) 
TOTAL 17 2 1 20  
 
* Out of the 30 patients of malignant germ cell tumours, follow up available 
for 20 patients, 9 patients defaulted and for one patient chemotherapy cycles 
are pending. 
* The median months of follow up is 24.5, maximum being 64 months and 
minimum being 3 months.  
* In the 20 patients followed, 17 patients were symptom free,2 patients 
presented with recurrent abdominal mass and 1 patient expired 
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* All the tumours showing CD117 positivity were symptom free. Symptoms 
recurred and one patient expired only in group  showing negativity for 
CD117 
TABLE - 20 
CORRELATION  OF GROSS FINDINGS WITH OUTCOME OF THE 
DISEASE 
GROSS 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
Solid 7(41.2%) 0(0%) 0(0%) 7 
 
P=0.577 
Cystic 2(11.8%) 0(0%) 0(0%) 2 
Mixed 8(47.1%) 2(100%) 1(100%) 11 
TOTAL 17(100%) 2(100%) 1(100%) 20(100%)  
 
* All the solid and cystic tumours were free of symptoms, only mixed germ 
cell tumour showed recurrence of the disease, but the correlation is not 
statistically significant. 
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TABLE – 21 
CORRELATION OF LATERALITY OF TUMOURS WITH OUTCOME OF 
THE DISEASE 
SIDE 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
RIGHT 8(47.1%) 2(100%) 1(00%) 11(55.0%)  
P=0.236 LEFT 9(52.9%) 0(0%) 0(0%) 9(45%) 
TOTAL 17(100%) 2(100%) 1(100%) 20(100%)  
 
* All left sided were free of symptoms, the disease recurrence and death 
occurred only in tumours of right side, but the correlation is not statistically 
significant. 
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TABLE – 22 
CORRELATION  OF USG FINDINGS WITH OUTCOME OF THE 
DISEASE 
USG 
FINDINGS 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
Solid 5(29.4%) 0(0%) 0(0%) 5(25%)  
P=0.754 Cystic 2(11.8%) 0(0%) 0(0%) 2(10%) 
Mixed 10(58.8%) 2(100%) 1(100%) 13(65%) 
TOTAL 17(100%) 2(100%) 1(100%) 20(100%)  
 
* The tumours which are solid and cystic in USG were asymptomatic, tumour 
recurrence and death occurred only in lesions showing mixed echogenicity, 
but the correlation is not statistically significant. 
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TABLE - 23 
CORRELATION OF HPE DIAGNOSIS WITH OUTCOME OF THE 
DISEASE 
HPE 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSO
N CHI 
SQUARE 
TEST 
DYSGERMIN
OMA 
7(41.2%) 0(0%) 0(%) 7(35%)  
 
 
P=0.221 
YOLK SAC 
TUMOUR 
3(17.6%) 0(0%) 0(%) 3(15%) 
IMMATURE 
TERATOMA 
4(23.5%) 0(0%) 0(%) 4(20%) 
MIXED GERM 
CELL 
TUMOUR 
3(17.6%) 2(100%) 1(100%) 6(30%) 
TOTAL 17 2 1 20(100%)  
 
* All dysgerminomas, yolk sac tumour and immature teratoma were free of 
tumour, symptoms persists in patients of mixed germ cell tumours, but the 
correlation is not statically significant. 
  
63
TABLE – 24 
CORRELATION OF STAGE  WITH OUTCOME OF THE  DISEASE 
 
STAGE 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
I 7(41.2%) 1(50%) 0(0%) 8(45%)  
P=0.906 II 1(5.9%) 0(0%) 0(0%) 1(5%) 
III 9(52.9%) 1(50%) 1(100%) 11(55%) 
TOTAL 17(100%) 2(100%) 1(100%) 20(100%)  
 
* All patients in stage I and stage II tumours are free of symptoms, only stage 
III tumours presents with recurrence and one patient expired. But this 
correlation is not statistically significant. 
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TABLE – 25 
CORRELATION OF CHEMOTHERAPY WITH OUTCOME OF THE  
DISEASE 
 
CHEMO 
THERAPY 
SYMPTOM 
FREE 
SYMPTOM 
PERSISTS 
EXPIRED TOTAL 
PEARSON 
CHI 
SQUARE 
TEST 
GIVEN 13(%) 2(100%) 1(100%) 16(%)  
P=0.643 NOT 
GIVEN 
4(%) 0(0%) 0(0%) 4(%) 
TOTAL 17(100%) 2(100%) 1(100%) 20(100%)  
 
* Disease recurrence and death occurred only in  patients who were given 
chemotherapy, whereas all patients who were  not given chemotherapy are 
symptom free  but the correlation is not statistically  significant. 
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CHART : 1- DISTRIBUTION OF BENIGN, BORDERLINE AND  
MALIGNANT CASES. 
 
 
CHART : 2 - DISTRIBUTION OF OVARIAN TUMOURS ACCORDING TO 
HISTOLOGICAL TYPE. 
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CHART : 3 - COMPARISION OF INCIDENCE OF BENIGN AND 
MALIGNANT GERM CELL TUMOURS. 
 
 
CHART :  4 - DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO TUMOUR TYPE. 
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CHART : 6 - DISTRIBUTION OF MALIGNANT GERM CELL TUMOURS 
ACCORDING TO LATERALITY OF TUMOURS. 
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CHART : 8 - COMPARISON OF MALIGNANT GERM CELL TUMOURS 
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CHART : 10 - PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT 
MALIGNANT GERM CELL TUMOURS. 
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CHART: 11 - PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT 
STAGES OF MALIGNANT GERM CELL TUMOURS. 
 
 
 
 
CHART : 12 COMPARISION OF C-KIT POSITIVITY IN MIXED GERM 
CELL TUMOURS WITH AND 
 WITHOUT DYSGERMINOMA COMPONENT 
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 CHART: 13  - COMPARISION OF PROPORTION OF BENIGN, 
BORDERLINE AND MALIGNANT CASES IN DIFFERENT STUDIES. 
 
 
CHART:  14 - COMPARISION OF HISTOLOGICAL TYPE OF OVARIAN 
TUMOURS IN DIFFERENT STUDIES. 
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 CHART: 15 - COMPARISION OF HISTOLOGICAL TYPES OF 
MALIGNANT GERM CELL TUMOURS IN DIFFERENT STUDIES 
 
 
CHART: 16 - COMPARISION OF STAGE OF DISEASE IN DIFFERENT 
STUDIES. 
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CHART: 17- COMPARISION OF LATERALITY OF GERM CELL 
TUMOURS. 
 
 
CHART: 18 - PERCENTAGE OF C-KIT POSITIVITY IN 
DYSGERMINOMA IN DIFFERENT STUDIES 
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CHART : 19 - PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT 
GERM CELL TUMOURS IN DIFFERENT STUDIES 
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FIG.1- 145/11-DYSGERMINOMA. 
 
 
FIG.2- 145/11-DYSGERMINOMA. 
 
 
 
  
                                   FIG.3-  2046/12-BILATERAL DYSGERMINOMA. 
 
 
FIG.4-1439/12-DYSGERMINOMA 
 
 
 
  
 
 
FIG.5-4280/07-YOLK SAC TUMOUR 
 
 
 
 
 
 
 
 
 
 
FIG.6- 4280/07-YOLK SAC TUMOUR 
 
  
 
 
FIG.7-2094/09-IMMATURE TERATOMA 
 
 
FIG.8- 3600/08-MIXED GERM CELL TUMOUR 
 
  
 
FIG.9-  2349/11-STRUMA OVARII. 
 
 
FIG.10  3286/11-DYSGERMINOMA 
 
 
  
 
 
 
 
 
 
 
FIG.11- 3286/11-DYSGERMINOMA WITH CYSTIC CHANGE 
 
 
 
 
 
 
 
  
 
FIG.12--DYSGERMINOMA X 10 
 
FIG.13--DYSGERMINOMA X40 
 
  
 
FIG.14--DYSGERMINOMA X10 
 
FIG.15--DYSGERMINOMA X40 
 
  
FIG.16--YOLK SAC TUMOUR X 10 
 
FIG.17--MIXED GERM CELL TUMOUR (YST IN LEFT AND DYSGERMINOMA IN 
RIGHT) X 10 
 
 FIG.18-IMMATURE TERATOMA SHOWING IMMATURE NEURAL ELEMENTS  X 
10 
 
FIG.19-IMMATURE TERATOMA SHOWING IMMATURE NEURAL ELEMENTS  X 
40 
 
 FIG.20-MIXED GERM CELL TUMOUR CONTAINING YST AND IMMATURE 
TERATOMA X 40 
 
FIG.21-C-KIT POSITIVITY IN DYSGERMINOMA (4+ STAINING)  X 10 
 
 
 FIG.22-C-KIT POSITIVITY IN DYSGERMINOMA (4+ STAINING) X 10 
 
 
FIG.23-C-KIT POSITIVITY IN DYSGERMINOMA (4+ STAINING) X 10 
 
 
FIG.24-C-KIT POSITIVITY IN DYSGERMINOMA (4+ STAINING) X 40 
 
FIG.25-C-KIT POSITIVITY IN DYSGERMINOMA (4+ STAINING) X 40 
 
 
 
 
FIG.26-C-KIT POSITIVITY IN DYSGERMINOMA (1+ STAINING) X 40 
 
FIG.27-C-KIT NEGATIVE CELLS IN DYSGERMINOMA (0 STAINING) X 40 
 
 
 
 
 
FIG.28-C-KIT POSITIVITY IN YOLK SAC TUMOUR (4+ STAINING) X 10 
 
FIG.29-C-KIT POSITIVITY IN YOLK SAC TUMOUR (4+ STAINING) X 40 
 
  
FIG.30-C-KIT NEGATIVITY  IN YOLK SAC TUMOUR (0 STAINING) X 40 
 
FIG.31-C-KIT POSITIVITY IN MIXED GERM CELL TUMOUR (BOTH YST AND 
DYSGERMINOMA ELEMENTS SHOWING POSITIVITY 
 (4+ STAINING) X 40 
 
 
  
FIG.32-C-KIT POSITIVITY IN  IMMATURE TERATOMA X 10 
 
FIG.33-C-KIT NEGATIVITY IN IMMATURE TERATOMA X 10. 
  
DISCUSSION 
* Ovarian cancers are important gynecological cancers having variable 
presentation. They tend to affect all age groups. Different histological type 
of tumours occurs in different age groups. 
 
* Germ cell malignancies generally affect younger women. 
 
* In our study, clinical and histopathological features of malignant germ cell 
tumours were studied and their immunohistochemical expression of c-kit is 
studied. 
 
* In our institute of obstetrics and gynecology, madras medical college we 
received a total of 725 ovarian neoplasms during a period of 70 months 
(from January 2007 - October 2012).  
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TABLE – 26 
COMPARISION OF PROPORTION OF BENIGN, BORDERLINE AND 
MALIGNANT CASES IN DIFFERENT STUDIES 
 
 Ahmad et al
85
 Pilli et al
86
 Gupta et al
87
 
Current 
study 
Benign. 59.18 75.2 72.9 67.13% 
Borderline  0.2 2.8 3.3 4.7% 
Malignant. 40.81 21.8 22.9 28.17% 
 
* Out of 725 cases 487 cases were benign, 34 cases  were borderline tumours  
and 204 cases were malignant. The distribution of benign, borderline and 
malignant cases in different studies by Ahmad et al
85
, Pilli et al
86
 and Gupta 
et al
87
 were studied (TABLE 26 and CHART 13). Current study incidence is 
more similar to study by Gupta et al. 
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TABLE – 27 
COMPARISION OF HISTOLOGICAL TYPE OF OVARIAN TUMOURS IN 
DIFFERENT STUDIES 
TUMOUR TYPE Jha et 
al
88
 
Pradhan et 
al
89
 
Swamy et 
al
90
 
Current 
study 
Surface epithelial 
tumours 
52.2% 46.9% 61.6% 75.5% 
Germ cell tumours 42.2% 45.7% 21.7% 16.5% 
Sex cord stromal 
tumours 
3.1% 3.6% 11.7% 7.2% 
Metastasis 2.4% 3.6% 5.0% 0.8% 
 
* The different histological types of ovarian tumours were compared with 
different studies by Jha eta l
88
, Pradhan et al
89
, Swamy et al
90 
(TABLE 27 
and CHART 14). Current study incidences are more correlating with study 
of  Swamy et al. 
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TABLE – 28 
COMPARISION OF HISTOLOGICAL TYPES OF MALIGNANT GERM 
CELL TUMOURS IN DIFFERENT STUDIES 
Tumour type 
S tangjitgamol 
et al
91
 (n-130) 
Chow et al
92 
(n-50) 
Present 
study (n-30) 
Dysgerminoma 37.7% 26% 36.66% 
Yolk sac tumour 26.2% 30% 13.34% 
Immature teratoma 23.1% 26% 16.66% 
Mixed germ cell tumour 13% 16% 33.34% 
TOTAL 100% 100% 100% 
 
* In germ cell tumours distribution of different histological subtypes was 
compared with  studies by Stangjitgamol et al
91
 and Chow et al
92 
(TABLE.28 
and CHART15) compared to both these studies incidence of yolk sac tumour 
is less in current study and incidence of mixed germ cell tumour is  more. 
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TABLE – 29 
COMPARISION OF MEAN AGE OF MALIGNANT GERM CELL 
TUMOURS IN DIFFERENT STUDIES 
 
Stangjitgamol 
et al
91
 
Lai et al
93
 Chow et al
92
 
Current 
study 
Mean age 21 yrs 23 yrs 21.5yrs 22.4yrs 
 
* The mean age of patients in current study group is 22.4 yrs which almost 
similar to studies by Stangjitgamol et al 
91 
(21 yrs), Lai et al
93  
(23 yrs) and 
Chow et al
92
 (21.5 yrs) (TABLE 29). 
 
* The mean size of all tumours is 15.7cm which is similar to study by Chow et 
al
92
  which is about 16cm. 
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TABLE – 30 
COMPARISION OF STAGE OF DISEASE IN DIFFERENT STUDIES 
STAGE 
Stangjitgamol    
et al
91
 
Debacker et al
94
 Current study 
I 63 52 11 
II 16 4 2 
III 41 6 17 
IV 3 1 0 
 
* The stage at presentation of tumours were compared with  studies by 
Stangjitgamol et al
91
 and Debacker et al
94 
(TABLE.30 and CHART.16). In 
both these studies presentation in stage I is common, but in our study 
presentation in stage III is more common. 
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TABLE – 31 
COMPARISION OF LATERALITY OF MALIGNANT GERM CELL 
TUMOURS 
LATERALITY Debacker et al
94
 Current study 
Right 35 18 
Left 28 11 
Bilateral 3 1 
TOTAL 66 30 
 
* The laterality of germ cell tumours is compared with Debacker et al
94
 
(TABLE.31 and CHART.17) which is similar to our study, more tumours on 
right side. 
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TABLE – 32 
PERCENTAGE OF C-KIT POSITIVITY IN DIFFERENT GERM CELL 
TUMOURS IN DIFFERENT STUDIES 
TUMOUR TYPE TRINH et al
95
 
CURRENT 
STUDY 
DYSGERMINOMA 100% 90.9% 
YOLK SAC TUMOUR 100% 50% 
IMMATURE TERATOMA 29% 20% 
 
 Percentage of c-kit positivity in germ cell tumour subtype is compared with 
study by Trihn et al
95  
(TABLE.32 and CHART.18)  Trihn et al
95
  reported 100% 
positivity of C-kit in both dysgerminoma and yolk sac tumour  and  a positivity of  
29% in cases of immature teratoma. Current study also showed similar results 
except lower positivity rate in cases of  yolk sac tumour. 
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TABLE – 33 
PERCENTAGE OF C-KIT POSITIVITY IN DYSGERMINOMA IN 
DIFFERENT STUDIES 
Author 
No of cases studied 
(dysgerminoma) 
% of cases showing 
c-kit positivity 
M sever et al
80
 30 87% 
Sakuma  et al
96
 16 100% 
Tsuura et al
52
 884 75% 
Present study 11 90.9% 
 
 Since  current study  emphasize more interest on dysgerminoma the 
percentage of C-kit positivity in various studies were compared (TABLE.33 and 
CHART 19).  Results of current study (81.8%)  are closer to the percentage 
obtained by M sever et al
80 
(87%) 
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SUMMARY 
* A total of 725 ovarian neoplasms were reported in our institution, benign 
cases were 487, borderline 34 cases and 204 malignant cases. 
 
* Surface epithelial tumours were common followed by germ cell tumours. 
 
* Common surface epithelial tumour is benign serous cystadenoma and 
common germ cell tumour is benign cystic teratoma. 
 
* In malignant ovarian tumours serous cystadenocarcinoma is the commonest 
tumour. 
 
* Among malignant germ cell tumours dysgerminoma is commonly observed. 
 
* The age incidence of germ cell tumours in current study ranges from 13 yrs 
to 40 yrs. 
 
* The mean age of the patients with malignant germ cell tumours is 22.4 yrs. 
 
* The average size of tumours is about 15.7 cm. 
 
* The mean age and size are correlating with various other studies. 
75
 * Dysgerminoma exhibits solid morphology in most cases. Mixed germ cell 
tumours and immature teratoma presents with mixed or variegated 
morphology. 
 
* Compared to other studies, in current study more patients are presented in 
stage III, whereas in other studies stage I presentation is more common 
followed by stage III. 
 
* The immunohistochemical expression of c-kit is more in dysgerminoma 
(90.9%) than the other malignant germ cell tumours. 
 
* In mixed germ cell tumours also, tumours having dysgerminoma as a 
component are expressing more c-kit positivity than tumours without 
dysgerminoma. 
 
* Yolk sac tumours show 50% positivity in current study which is 
comparatively compared to other studies. 
 
* In Immature teratoma c-kit positivity is about  20% in our study, which is 
almost to similar to other studies. 
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* Out of the 20 patients followed up 17 patients were alive and symptom free, 
2 patient  have recurrent abdominal mass, 1 patient  expired. 
 
* The correlation between the Immunohistochemical expression of c-kit and 
the clinical parameters is not statistically significant. 
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CONCLUSION 
Malignant germ cell tumours are the second common group of ovarian 
malignancy after surface epithelial malignancies. 
Since they are affecting the reproductive age group people, preserving the 
fertility with cure of the patient is a big challenge. 
Dysgerminoma, the ovarian counterpart of seminoma is the common germ 
cell malignancy occurring in younger age group with a peak incidence in second 
and third decades. 
Expression of c-kit in dysgerminoma is similar to its counterpart seminoma. 
Though the germ cell malignancies are responding better to platinum based 
chemotherapy given in our institutional set up, the possible risk of infertility is 
there. 
Targeted therapy against c-kit is available for disease like chronic myeloid 
leukemia, GIST, it can be of use in germ cell tumours too. 
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But even in a tertiary hospital like IOG, MMC the incidence of germ cell 
tumours is only 30 cases for a period of 70 months period. 
Hence trials involving a large group of people with germ cell tumours 
should be done for evaluation of c-kit expression and positive c-kit cases should be 
tried with anti-c kit compounds like imatinib so that it could be effective 
alternative for conventional platinum based regimens. 
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ANNEXURE I 
PROFORMA. 
 
Name: 
 
Age: 
 
Address: 
 
Ip no: 
 
Biopsy no: 
 
Presenting complaints: 
 
Obstetric history: 
 
USG/CT/MRI Findings: 
 
Hormonal levels (AFP,CEA,β-HCG,LDH): 
 
Surgical procedure done: 
 
FIGO STAGE: 
 
HPE Diagnosis: 
 
Chemotherapy details: 
 
 Chemo given or not 
 
 If given , no of cycles and regimen used. 
 
Months of follow up: 
 
Outcome of the patient: 
 
 
                                    ANNEXURE II 
 
WHO classification of ovarian tumours. 
Surface epithelial–stromal tumors 
Serous tumors 
  Malignant 
    Adenocarcinoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
Mucinous tumors 
  Malignant 
    Adenocarcinoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
  Mucinous cystic tumor with pseudomxoma peritonei 
Endometrioid tumors including variants with squamous differentiation 
  Malignant 
    Adenocarcinoma 
    Malignant mixed müllerian tumor (carcinosarcoma) 
    Endometrioid stromal sarcoma (low grade) 
    Undifferentiated ovarian sarcoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
Clear cell tumors 
  Malignant 
    Adenocarcinofibroma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
Transitional cell tumors 
  Malignant 
    Transitional cell carcinoma (non-Brenner type) 
    Malignant Brenner tumor 
  Borderline 
  Benign 
    Brenner tumor 
Squamous cell tumors 
  Squamous cell carcinoma 
Mixed epithelial tumors (specify components) 
  Malignant 
  Borderline 
  Benign 
Undifferentiated and unclassified tumors 
  Undifferentiated carcinoma 
  Adenocarcinoma, not otherwise specified 
Sex-cord stromal tumors 
Granulosa-stromal cell tumors 
  Granulosa cell tumor group 
    Adult granulosa cell tumor 
    Juvenile granulosa cell tumor 
Thecoma-fibroma group 
  Thecoma, not otherwise specified 
    Typical 
    Luteinized 
  Fibroma 
  Cellular fibroma 
  Fibrosarcoma 
  Stromal tumor with minor sex cord elements 
  Sclerosing stromal tumor 
  Signet-ring stromal tumor 
  Unclassified (fibrothecoma) 
Sertoli-stromal cell tumors 
  Sertoli-Leydig cell tumor group 
    Well differentiated 
    Of intermediate differentiation 
      Variant with heterologous elements (specify type) 
    Poorly differentiated (sarcomatoid) 
      Variant with heterologous elements (specify type) 
    Retiform 
      Variant with heterologous elements (specify type) 
  Sertoli cell tumor 
  Stromal-Leydig cell tumor 
  Sex cord-stromal tumors of mixed or unclassified cell types 
  Sex cord tumor with annular tubules 
  Gynandroblastoma (specify components) 
  Sex cord-stromal tumor, unclassified 
Steroid cell tumors 
  Stromal luteoma 
  Leydig cell tumor group 
    Hilus cell tumor 
    Leydig cell tumor, nonhilar type 
    Leydig cell tumors, not otherwise specified 
  Steroid cell tumor, not otherwise specified 
    Well differentiated 
    Malignant 
Germ cell tumors 
Primitive germ cell tumors 
Dysgerminoma 
Yolk sac tumor 
Embryonal carcinoma 
Polyembryoma 
Nongestational choriocarcinoma 
Mixed germ cell tumor (specify components) 
Biphasic or triphasic teratoma 
Immature teratoma 
Mature teratoma 
  Solid 
  Cystic 
  Fetiform teratoma (homunculus) 
Monodermal teratoma and somatic-type tumors associated with dermoid cysts 
Thyroid tumor group 
  Struma ovarii 
    Benign 
    Malignant (specify type) 
Cardinoid group 
Neuroectodermal tumor group 
Carcinoma group 
Melanocytic group 
  Malignant melanoma 
  Melanocytic nevus 
Sarcoma group (specify type) 
Sebaceous tumor group 
Pituitary-type tumor group 
Retinal anlage tumor group 
Others 
Germ cell sex cord-stromal tumors 
Gonadoblastoma 
  Variant with malignant germ cell tumor 
Mixed germ cell-sex cord-stromal tumor 
  Variant with malignant germ cell tumor 
Tumors of the rete ovarii 
Adenocarcinoma 
Adenoma 
Cystadenoma 
Cystadenofibroma 
Miscellaneous tumors 
Small cell carcinoma, hypercalcemic type 
Small cell carcinoma, pulmonary type 
Large cell neuroendocrine carcinoma 
Hepatoid carcinoma 
Primary ovarian mesothelioma 
Wilms tumor 
Gestational choriocarcinoma 
Hydatidiform mole 
Adenoid cystic carcinoma 
Basal cell tumor 
Ovarian 
Wolffian tumor 
Paraganglioma 
Myxoma 
Soft tissue tumors not specific to the ovary 
Others 
Tumorlike conditions 
Luteoma of pregnancy 
Stromal hyperthecosis 
Stromal hyperplasia 
Fibromatosis 
Massive ovarian edema 
Others 
Lymphoid and hematopoetic tumors 
Malignant lymphoma (specify type) 
Leukemia (specify type) 
Plasmacytoma 
Secondary tumors 
 
 
ANNEXURE III 
 
FIGO STAGING OF OVARIAN CANCERS. 
 
Stage I -Growth limited to the ovaries. 
 
 IA -Growth limited to one ovary; no ascites present containing malignant 
cells. No tumor on the external surface; capsule intact. 
 
IB- Growth limited to both ovaries; no ascites present containing malignant 
cells. No tumor on the external surface; capsule intact. 
 
IC- Tumor classified as either Stage IA or IB but with tumor on the surface 
of one or both ovaries; or with ruptured capsule(s); or with ascites 
containing malignant cells or with positive peritoneal washings. 
 
Stage II -Growth involving one or both ovaries, with pelvic extension. 
 
IIA -Extension and/or metastases to the uterus and/or tubes. 
 
IIB- Extension to other pelvic tissue. 
 
IIC- Tumor classified as either Stage IIA or IIB but with tumor on the 
surface of one or both ovaries; or with capsule(s) ruptured; or with ascites 
containing malignant cells or with positive peritoneal washings. 
 
Stage III- Tumor involving one or both ovaries with peritoneal implants outside the 
pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis 
equals Stage III.Tumor is limited to the true pelvis but with histologically proven 
malignant extension to small bowel or omentum. 
 
IIIA- Tumor grossly limited to the true pelvis with negative nodes but with 
histologically confirmed microscopic seeding of abdominal peritoneal 
surfaces. 
 
IIIB -Tumor of one or both ovaries with histologically confirmed implants of 
abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes are 
negative. 
 
IIIC- Abdominal implants greater than 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
 
Stage IV -Growth involving one or both ovaries, with distant metastases. If pleural 
effusion is present, there must be positive cytological findings to allot a case to 
Stage IV.Parenchymal liver metastasis equals Stage IV. 
 
 
 
                                      
 
 
 
 
 
 
 
ANNEXURE IV 
 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4μ thick sections were cut from formalin fixed paraffin embedded tissue samples 
and transferred to gelatin-chrome alum coated slides. 
 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running tap 
water for 5 minutes. 
 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (citrate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in citrate buffer for 5 minutes x 2 changes. 
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 1 hour (CD117). 
15. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in citrate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 ml of 
DAB buffer. 
 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with citrate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds (1 dip). 
 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX 
 
  
S.NO BX NO 
AGE 
IN YRS 
SEX SIDE P/D SIZE USG GROSS HPE STAGE CHEMO CD117 
FOLLOW 
UP 
COURSE 
1 456/07 20 F LFT L.OVAR 25 X 25 X15 CM MIXED MIXED MGCT III C 4BEC 4+ 62mths sym free 
2 730/07 29 F RT 
TAH,R.OV
AR 
30 X 30 X 10 CM MIXED MIXED MGCT III 4BEC 3+ 60mths sym free 
3 1923/07 17 F LFT L.OVAR 15 X10 CM MIXED MIXED IMM.TER I C 3BEC 3+ 55mths sym free 
4 2651/07 27 F LFT LSCS,LSO 22 X20 CM SOLID SOLID MGCT III 4BEC 3+ 10mths sym free 
5 3072/07 16 F RT R.OVAR 12 X 10 X7 CM CYS MIXED IMM.TER I C 
NO 
CHEMO 
NEG 24mths sym free 
6 4046/07 20 F RT R.OVAR 30 X 23 X 7 CM MIXED MIXED MGCT III 
NO 
CHEMO 
1+ DEF - 
7 4280/07 40 F LFT TAH,BSO 15 X15 X 7 CM MIXED MIXED YST I C 4BEC 1+ 19 mths sym free 
8 156/08 18 F LFT L.OVAR 16 X 12 X 6 CM MIXED CYST IMM.TER II 4 BEC NEG 51 mths sym free 
9 165/08 16 F RT B/L OVAR 21 X 11 CM MIXED MIXED YST IIIC 4 BEC NEG 55 mths sym free 
10 2993/08 25 F LFT TAH,BSO 12 X 6 X 6 CM MIXED SOLID MGCT III A 4BEC 4+ 16mths sym free 
11 3600/08 20 F RT R.OVAR 12 X 10 X 4 CM MIXED MIXED IMM.TER III 3BEC NEG DEF - 
12 7509/08 13 F RT TAH,BSO 8 X 7  X 5 CM SOLID SOLID DYSG I A 
NO 
CHEMO 
3+ DEF - 
13 361/09 18 F RT R.OVAR 21 X 18 X 12 CM MIXED MIXED MGCT I A 4BEC 2+ DEF - 
14 2212/08 25 F LFT TAH,BSO 12 X6 X 6 CM MIXED SOLID DYSG IIIA 1 BEC 4+ DEF - 
15 2094/09 28 F RT TAH,BSO 15 X 12 X 5 CM MIXED MIXED MGCT III C 4 BEC NEG 6 mths RECUR 
S.NO BX NO 
AGE 
IN YRS 
SEX SIDE P/D SIZE USG GROSS HPE STAGE CHEMO CD117 
FOLLOW 
UP 
COURSE 
16 2780/09 28 F RT TAH,BSO 15 X 12 X 5 CM MIXED MIXED MGCT III C I BEC NEG 4mths Expired 
17 3141/09 32 F RT R.OVAR 20 X 20 X15 CM MIXED SOLID MGCT IIIC 
NO 
CHEMO 
1+ DEF - 
18 3399/09 28 F RT TAH,BSO 25 X 20 X 15 CM MIXED MIXED YST III C 
NO 
CHEMO 
NEG DEF - 
19 3909/09 18 F LFT L.OVAR 11 X 10 X 8 CM SOLID SOLID DYSG I A 
NO 
CHEMO 
NEG DEF - 
20 4A/10 13 F RT DEBULK 13 X 10 CM MIXED MIXED YST III 3BEC 3+ 30 mths sym free 
21 824/10 22 F LFT L.OVAR 11 X11 X 7 CM SOLID SOLID DYSG I 4 BEC 2+ 25 mths sym free 
22 1231/10 15 F RT R.OVAR 16 X 10 X 6 CM MIXED SOLID DYSG III C 4 BEC 2+ 27 mths sym free 
23 1431/10 21 F RT R.OVAR 10 X 9 X 6CM MIXED SOLID DYSG IA 2 BEC 3+ 22 mths sym free 
24 2513/10 38 F RT TAH,BSO 8 X 7 X 7 CM MIXED MIXED MGCT I C 4 BEC NEG 5 mths RECUR 
25 3286/10 17 F RT R.OVAR 14 X 12 X 5 CM SOLID MIXED DYSG III C 4BEC 1+ 5mths sym free 
26 101/11 30 F LFT LSO 9 X 5 X 3 CM CYS CYS IMM.TER III C 
NO 
CHEMO 
NEG 3mths sym free 
27 145/11 23 F LFT LSO 9 X 7 X 3 CM SOLID SOLID DYSG I A 
NO 
CHEMO 
3+ 14 mths sym free 
28 3201/11 20 F RT RSO 11 X7 X 5 CM MIXED SOLID DYSG III C 3 BEC 2+ DEF - 
29 1439/12 16 F RT RSO 15 X10 X9 CM SOLID SOLID DYSG I 
NO 
CHEMO 
4+ 3mths sym free 
30 2046/12 21 F B/L DEBULK 19 X 13 X 6 CM SOLID SOLID DYSG II B 2BEC 4+ chemo pend - 
 
KEY TO MASTER CHART 
 
Bx no-biopsy number. 
 
F-female. 
 
RT- right. 
 
LFT-left. 
 
B/L-bilateral. 
 
P/D-procedure done. 
 
R.OVAR-right ovariotomy. 
 
L.OVAR-left ovariotomy. 
 
RSO-right salphingo oopherectomy. 
 
LSO-left salphingo oopherectomy. 
 
TAH-total abdominal hysterectomy. 
 
BSO-bilateral salphingo oopherectomy. 
 
DEBULK-debulking. 
 
CM-centimeter. 
 
CYS-cystic. 
 
HPE-histopathological examination. 
 
DYSG-dysgerminoma. 
 
IMMAT.TER-immature teratoma. 
 
YST-yolk sac tumour. 
 
MGCT-mixed germ cell tumour. 
 
BEC-bleomycin,etoposide,cisplatin. 
 
NEG-negative. 
 
Mths-months. 
 
DEF-default. 
 
Chemo pen-chemo pending. 
 
Sym free-symptom free. 
 
REC-recurrence.
 
                                                ABSTRACT. 
AIM: 
The aim of current study is to know about the incidence of ovarian cancers, study 
about the histomorphological features of malignant germ cell tumours and also the 
immunohistochemical expression of CD117 with special emphasis on 
dysgerminoma of ovary, in patients admitted in Institute of Obstetrics and 
Gynaecology, Egmore, Madras Medical College. 
MATERIALS AND METHODS: 
The detailed case history of all the ovarian cancers were collected retrospectively 
and the paraffin blocks of 30 cases of malignant germ cell tumours were collected 
and subjected for immunohistochemical study of CD117 expression. The 
expression of CD117 is correlated with various clinico pathological parameters 
using pearson chi square test. 
OBSERVATION AND RESULTS: 
A total of 725 cases of ovarian neoplasms are observed, out of which 487 cases are 
benign, 34 cases are borderline and 204 cases are malignant. Among the malignant 
germ cell tumours observed, 11cases were dysgerminoma, 10 cases were mixed 
germ cell tumour, 5cases were immature teratoma and 4 cases were yolk sac 
tumour.90.9% of dysgerminoma, 70% of mixed germ cell tumour, 50% of yolk sac 
tumour and 20% of immature teratoma were positive for CD117. 
CONCLUSION: 
The incidence of malignant germ cell tumours is very less even in a tertiary 
hospital like MMC, hence trials involving a large group of people with germ cell 
tumours should be done for evaluation of c-kit expression and positive c-kit cases 
should be tried with anti-c kit compounds like imatinib so that it could be effective 
alternative for conventional platinum based regimens. 
Key words: malignant germ cell tumours, dysgerminoma, CD117. 
 
 
